IP Library Granted Patent US 12,054,706
Granted Patent B2
US 12,054,706 · App. 17/830,011 · Granted Aug 6, 2024

Methods for targeted insertion of DNA in genes

Inventor: Nicholas J. Baltes (Oakdale, MN)
Assignee: BLUEALLELE CORPORATION
C12N15/102C12N15/86C12N15/907C12N2310/20C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,054,706
App. No.
17/830,011
Granted
Aug 6, 2024
Kind
B2
Abstract

Methods and compositions for modifying the coding sequence of endogenous genes using rare-cutting endonucleases and transposases. The methods and compositions described herein can be used to modify the coding sequence of endogenous genes.

Claims (14)

1. A vector comprising a transgene comprising from 5′ to 3′ orientation:

a first splice acceptor, a first coding sequence, a first terminator, a second terminator reverse complement, a second coding sequence reverse complement, and a second splice acceptor reverse complement,

wherein the first coding sequence is operably linked to the first splice acceptor and first terminator, and the second coding sequence is operably linked to the second splice acceptor and second terminator, wherein the first and second coding sequences differ in nucleic acid sequence but encode the same amino acids,

wherein said amino acids encoded by the first and second coding sequences correspond to amino acids encoded by an endogenous Factor VIII gene, and

wherein the transgene is equal to or less than 4.7 kb.

2. The vector of claim 1 , wherein the first terminator is selected from an SV40 poly(A) or BGH poly(A).

3. The vector of claim 2 , wherein the second terminator is selected from an SV40 poly(A) or BGH poly(A).

4. The vector of claim 3 , wherein the amino acids encoded by the first and second coding sequences have at least 80% sequence identity to the amino acids encoded by the endogenous Factor VIII gene, wherein the percent sequence identity is calculated by matching amino acids encoded by the first and second coding sequence with amino acids encoded by an endogenous Factor VIII gene and dividing the number of matches by the length of the amino acids encoded by the first and second coding sequence, followed by multiplying the resulting value by 100.

5. The vector of claim 4 , wherein the amino acids encoded by the first and second coding sequences have about 98% sequence identity to the amino acids encoded by an endogenous Factor VIII gene.

6. The vector of claim 4 , wherein the amino acids encoded by the first and second coding sequences have about 99% sequence identity to the amino acids encoded by an endogenous Factor VIII gene.

7. The vector of claim 4 , wherein the vector is a viral vector.

8. The vector of claim 7 , wherein the viral vector is selected from the group consisting of an adenovirus vector, an adeno-associated virus vector, and a lentivirus vector.

9. The vector of claim 8 , wherein the viral vector is an adeno-associated viral vector.

10. The vector of claim 9 , wherein the first splice acceptor comprises a splice acceptor sequence from an intron of the endogenous Factor VIII gene.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2023
From: BALTES, NICHOLAS
To: BLUEALLELE CORPORATION
Reel/Frame 062450/0698 →
Continuity (8)
Continuation 17590613 · Feb 1, 2022
Continuation 17366290 · Jul 2, 2021
Continuation 16800444 · Feb 25, 2020
Continuation 16601144 · Oct 14, 2019
Provisional Application 62864432 · Jun 20, 2019
Provisional Application 62830654 · Apr 8, 2019
Provisional Application 62746497 · Oct 16, 2018
Related Publication 20230212553A1 · Jul 6, 2023
Cited By (1)
US 12,441,994